BG105736A - 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors - Google Patents
2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitorsInfo
- Publication number
- BG105736A BG105736A BG105736A BG10573601A BG105736A BG 105736 A BG105736 A BG 105736A BG 105736 A BG105736 A BG 105736A BG 10573601 A BG10573601 A BG 10573601A BG 105736 A BG105736 A BG 105736A
- Authority
- BG
- Bulgaria
- Prior art keywords
- matrix metalloproteinase
- benzodiasepine
- tetrahydro
- hydroxamic acid
- metalloproteinase inhibitors
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- -1 tumor growth Chemical compound 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908099A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/001991 WO2000044730A1 (en) | 1999-01-27 | 2000-01-27 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105736A true BG105736A (en) | 2002-05-31 |
Family
ID=22900512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105736A BG105736A (en) | 1999-01-27 | 2001-07-26 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1147095B1 (cs) |
| JP (1) | JP2002535392A (cs) |
| KR (1) | KR20010101730A (cs) |
| CN (1) | CN1197849C (cs) |
| AR (1) | AR022423A1 (cs) |
| AT (1) | ATE273288T1 (cs) |
| AU (1) | AU767039B2 (cs) |
| BG (1) | BG105736A (cs) |
| BR (1) | BR0007759A (cs) |
| CA (1) | CA2356267A1 (cs) |
| CZ (1) | CZ20012637A3 (cs) |
| DE (1) | DE60012883T2 (cs) |
| EA (1) | EA200100809A1 (cs) |
| ES (1) | ES2223470T3 (cs) |
| HU (1) | HUP0105302A3 (cs) |
| ID (1) | ID29046A (cs) |
| IL (1) | IL144168A0 (cs) |
| NO (1) | NO20013675L (cs) |
| NZ (1) | NZ511885A (cs) |
| PL (1) | PL349025A1 (cs) |
| PT (1) | PT1147095E (cs) |
| SK (1) | SK10422001A3 (cs) |
| TR (1) | TR200102131T2 (cs) |
| WO (1) | WO2000044730A1 (cs) |
| ZA (1) | ZA200104321B (cs) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| US7488754B2 (en) | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
| AU2003253176A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
| ATE520935T1 (de) | 2003-05-21 | 2011-09-15 | Alexza Pharmaceuticals Inc | Verwendung einer schicht aus festem brennstoff, verfahren zum erstellen einer solchen schicht und zugehörige heizvorrichtung |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| AU2005263762C1 (en) * | 2004-07-21 | 2012-03-01 | Merck Serono Sa | Octahydropyrrolo[2, 3, c]pyridine derivatives and pharmaceutical use thereof |
| EP2246086A3 (en) | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
| DK2041181T3 (da) * | 2006-06-08 | 2011-08-29 | Helmholtz Zentrum Muenchen | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| FR2950056B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2950057B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| AU2011274972B2 (en) | 2010-07-08 | 2014-02-20 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and medicament containing same |
| CA2811504C (en) * | 2010-09-17 | 2018-06-05 | Kaken Pharmaceutical Co., Ltd. | Composition for maintaining function of platelets |
| WO2019152873A1 (en) | 2018-02-02 | 2019-08-08 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
| US20220370463A1 (en) * | 2019-09-19 | 2022-11-24 | New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special S | Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| DE69519751T2 (de) * | 1995-04-20 | 2001-04-19 | Pfizer Inc., New York | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
| DE59608740D1 (de) * | 1995-11-13 | 2002-03-21 | Hoechst Ag | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren |
| ES2195034T3 (es) * | 1995-12-08 | 2003-12-01 | Agouron Pharma | Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion. |
| US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| HUP0000130A2 (hu) * | 1996-08-28 | 2000-06-28 | The Procter And Gamble Co. | 1,3-Heterociklusos fémproteáz inhibitorok |
| DK0925287T3 (da) * | 1996-08-28 | 2003-05-12 | Procter & Gamble | Heterocykliske metalloproteaseinhibitorer |
| DK0923561T3 (da) * | 1996-08-28 | 2003-02-24 | Procter & Gamble | Heterocykliske metalloproteaseinhibitorer |
| PL342045A1 (en) * | 1998-01-27 | 2001-05-21 | American Cyanamid Co | 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases |
-
2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Withdrawn
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en not_active Ceased
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
-
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60012883T2 (de) | 2005-08-25 |
| SK10422001A3 (sk) | 2002-09-10 |
| CN1197849C (zh) | 2005-04-20 |
| IL144168A0 (en) | 2002-05-23 |
| EA200100809A1 (ru) | 2002-02-28 |
| EP1147095B1 (en) | 2004-08-11 |
| DE60012883D1 (de) | 2004-09-16 |
| EP1147095A1 (en) | 2001-10-24 |
| HUP0105302A2 (hu) | 2002-07-29 |
| CA2356267A1 (en) | 2000-08-03 |
| AU767039B2 (en) | 2003-10-30 |
| WO2000044730A1 (en) | 2000-08-03 |
| JP2002535392A (ja) | 2002-10-22 |
| HUP0105302A3 (en) | 2002-09-30 |
| KR20010101730A (ko) | 2001-11-14 |
| TR200102131T2 (tr) | 2001-12-21 |
| NO20013675D0 (no) | 2001-07-26 |
| ES2223470T3 (es) | 2005-03-01 |
| CN1337952A (zh) | 2002-02-27 |
| CZ20012637A3 (cs) | 2002-04-17 |
| AR022423A1 (es) | 2002-09-04 |
| ATE273288T1 (de) | 2004-08-15 |
| BR0007759A (pt) | 2001-11-13 |
| NZ511885A (en) | 2003-06-30 |
| PL349025A1 (en) | 2002-07-01 |
| PT1147095E (pt) | 2004-12-31 |
| AU3216000A (en) | 2000-08-18 |
| NO20013675L (no) | 2001-09-21 |
| ZA200104321B (en) | 2002-08-26 |
| ID29046A (id) | 2001-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105736A (en) | 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors | |
| BR0010598A (pt) | Azoles substituìdos | |
| UA72910C2 (uk) | АЦЕТИЛЕНОВІ, ОСНОВАНІ НА <font face="Symbol">a</font>-АМІНОКИСЛОТАХ, ПОХІДНІ СУЛЬФОНАМІДІВ ГІДРОКСАМОВИХ КИСЛОТ, ЯКІ ІНГІБУЮТЬ TACE, СПОСІБ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ), ПРОМІЖНА СПОЛУКА (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПАТОЛОГІЧНИХ ЗМІН, ПОВ'ЯЗАНИХ З УЧАСТЮ ТАСЕ, І ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ | |
| MXPA04000622A (es) | Pirazolilcarboxanilidas como funguicidas. | |
| GR3029449T3 (en) | (e)-20(22)-dehydrovitamin d compounds | |
| BR0214805A (pt) | Lama viscosa de alta perda de fluido solúvel em ácido para circulação perdida | |
| DE69912479D1 (de) | 4- und 5-alkynyloxindole sowie 4- und 5-alkenyloxindole | |
| AU6276700A (en) | Liquid-crystalline medium | |
| EP1077218A3 (en) | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors | |
| TR28332A (tr) | Arilasetik asit türevleri. | |
| BR9809429A (pt) | Diazepinoindolonas inibidoras de fosfodiesterase 4 | |
| NZ512446A (en) | Alkynyl containing hydroxamic acid compounds as TACE inhibitors | |
| PL336640A1 (en) | Substituted 3,3-diamino-2- propenonitriles, their production and application | |
| ATE280152T1 (de) | Acetylenische sulfonamid-thiol-tace-inhibitoren | |
| ATE288922T1 (de) | Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen | |
| BG105003A (en) | Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer | |
| GB2324528A (en) | Cytostatic hydroxamic acid derivatives | |
| GB9923710D0 (en) | Chemical compounds | |
| PT1144369E (pt) | Acidos hidroxamicos de arilsulfonamidas acetilenicas e de amidas de acido fosfinico acetilenicas inibidores de tace | |
| AU2566101A (en) | Compounds and methods for the treatment of pain | |
| EA200100808A1 (ru) | ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE | |
| ID27440A (id) | Proses untuk menyiapkan penengah-penengah | |
| BR0007726A (pt) | Composto, processo para preparar o mesmo,método de inibir mudanças patológicas, e,composição farmacêutica. | |
| HUT56550A (en) | Process for producing 4-chloro-3-sulfamoylbenzoic acid hydrazides and pharmaceutical compositions comprising such compounds | |
| BG105618A (en) | Beta-amido and beta-sulphonamide derivatives of carboxylic acids, method for preparation and application as endothelin-receptor antagonists |